LYTACs- open access papers
LYTACs open access research articles 2023
Added 'research articles' for specificity and included the year 2023 to target the most recent publications on LYTACs.
… These interesting findings revealed that our covalent LYTAC may directly induce immunogenic apoptosis of tumor cells after PD-L1 degradation and display higher immunogenicity for …
… In conclusion, the scientific field has witnessed considerable advancements in LYTAC technology (Table 1), marked by the development of new techniques that enhance its application …
Recent advancements in Lysosome-Targeting Chimeras (LYTACs) have spurred considerable interest in their potential for targeted protein degradation. Here’s a roundup of the latest open-access research articles published in 2023 and beyond, which delve into various aspects of LYTAC technology.
Overview of LYTACs
LYTACs represent a cutting-edge innovation in biopharmaceuticals, designed to facilitate the lysosomal degradation of specific membrane and extracellular proteins. By linking these proteins to lysosomal targeting motifs, LYTACs can effectively direct unwanted proteins for degradation, a mechanism with significant implications for therapeutic interventions, particularly in oncology and other diseases.
Key Open-Access Papers
1. Targeted Degradation of Membrane and Extracellular Proteins
The study detailed in Nature explores the innovative techniques developed for enhancing LYTAC applications. The findings indicate that recent advancements have significantly improved the specificity and efficiency of LYTACs in degrading targeted proteins, which could pave the way for novel therapeutic strategies.
2. Catalytic Degradation of Circulating Targets
A preprint available on bioRxiv discusses the use of FcRn-mediated cycling in LYTACs, demonstrating the potential for prolonged action of these molecules when positioned strategically. This research emphasizes the importance of timing and dosage in maximizing the efficacy of LYTAC therapies.
3. IGF2 Peptide-Based LYTACs
An article in MDPI highlights the novel IGF2 peptide-based LYTACs that are designed to target extracellular and transmembrane proteins. This research underlines the versatility of LYTACs in engaging different types of proteins, which could lead to broader therapeutic applications.
4. VEGF-Degrading LYTACs
Research published in PMC focuses on VEGF-degrading LYTACs (VED-LYTACs) and their effectiveness in mitigating pathological retinal angiogenesis. This work provides insight into their potential use in treating disorders related to abnormal blood vessel growth.
5. Phototriggered LYTAC
Another innovative approach is discussed in the publication by the American Chemical Society, which introduces a phototriggered mechanism to enhance the degradation of membrane proteins via LYTACs. This advancement showcases the potential for developing highly regulated therapeutic strategies using light activation.
6. Genetically Encoded LYTACs
The Proceedings of the National Academy of Sciences (PNAS) published findings on the "directed evolution" of genetically encoded LYTACs, offering a glimpse into the future of precision medicine. This research emphasizes the feasibility of using synthetic glycopeptides for more reliable targeting in therapeutic applications (PNAS).
Conclusion
As indicated by the recent literature, the field of LYTAC technology is rapidly evolving, with promising strategies emerging for targeted protein degradation. The open-access papers from 2023 provide a wealth of knowledge that could pave the way for transformative therapies in various diseases. Continuing research in this area holds the potential to unlock new horizons in medical science, particularly in the realm of precision medicine. For those interested in further exploring this topic, reviewing these sources can offer valuable insights into the mechanisms and potential applications of LYTACs.
Sources
10… These interesting findings revealed that our covalent LYTAC may directly induce immunogenic apoptosis of tumor cells after PD-L1 degradation and display higher immunogenicity for …
… In conclusion, the scientific field has witnessed considerable advancements in LYTAC technology (Table 1), marked by the development of new techniques that enhance its application …
… These initial results motivated us to further explore the duration of action for stabilized LYTACs by increasing the delay between LYTAC and target administration up to 7 days, and by …
… (LYTACs) have recently been developed to facilitate the lysosomal degradation of specific extracellular and transmembrane molecular targets. However, the LYTAC … protein LYTACs …
… VEGF-degrading LYTACs (VED-LYTACs). The engineered VED-LYTACs exhibit high affinity … Animals had free access to food and water and were exposed to normal lighting conditions …
… LYTAC) holds significant promise in addressing various diseases. However, the precise structural control of LYTAC … multifunctional phototriggered LYTAC platform, named PT-LYTAC, to …
… and LYTACs are pushing … LYTACs are poised to address unmet needs in oncology, neurodegeneration, infectious disease, and rare genetic disorders. This article explores the scientific …
Highlights • Degradation strategies towards extracellular and membrane proteins were summarized. • The composition, construction strategy and mechanism of degradation strategies …
… of LYTAC contain synthetic glycopeptides that cannot be genetically encoded. Here, we present our designs for a fully genetically encodable LYTAC (… portion of LYTACs with the protein …
… Bertozzi) and Avilar Therapeutics, have undergone translational research around LYTAC technology. We look forward to these new discoveries driving LYTAC into novel therapies that …